| 2007 | | 5-fluorouracil, mitomycin-C, and polysaccharide-K adjuvant chemoimmunotherapy for locally advanced gastric cancer: the prognostic significance of frequent perineural invasion | 김명욱, 김영배, 김효철, 박준성, 조용관, 주희재, 최진혁, 한상욱 |
| 2013 | | 5-Fluorouracil, mitomycin-c, and polysaccharide-k versus uracil-ftorafur and polysaccharide-K as adjuvant chemoimmunotherapy for patients with locally advanced gastric cancer with curative resection. | 강석윤, 박준성, 안미선, 이광재, 이순영, 이현우, 정성현, 조용관, 최진혁, 한상욱 |
| 2023 | | Adding Ovarian Suppression to Tamoxifen for Premenopausal Women with Hormone Receptor-Positive Breast Cancer after Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial | 백수연, 정용식 |
| 2021 | | Appropriate Number of Adjuvant Chemotherapy Cycles for Patients with Stage 2 or 3 Gastric Cancer After Curative Gastrectomy: A Multicenter Cohort Study | 허훈 |
| 2024 | | Breast density reduction as a predictor for prognosis in premenopausal women with estrogen receptor-positive breast cancer: an exploratory analysis of the updated ASTRRA study | 정용식 |
| 2015 | | Does the timing of adjuvant chemotherapy for gastric cancer influence patient outcome? | 강석윤, 박준성, 신승수, 안미선, 이현우, 정성현, 조용관, 최용원, 최진혁, 한상욱, 한재호 |
| 2020 | | Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer | 정용식 |
| 2017 | | Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study | 서광욱 |
| 2002 | | Expression of multidrug resistance-associated protein1,P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection. | 김명욱, 김효철, 이기범, 임호영, 조용관, 주희재, 최진혁 |
| 2001 | | Expression of thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection. | 김명욱, 김현수, 김효철, 남동기, 이기범, 임호영, 조용관, 주희재, 최진혁 |
| 2021 | | Five-year changes in ovarian function restoration in premenopausal patients with breast cancer taking tamoxifen after chemotherapy: An ASTRRA study report | 정용식, 한세환 |
| 2016 | | Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial | 한상욱 |
| 2013 | | Magnetic resonance imaging enhancement features before and after neoadjuvant chemotherapy in patients with breast cancer: a predictive value for responders. | 강두경, 김구상, 김태희, 임현이 |
| 2012 | | Magnetic resonance imaging patterns of tumor regression after neoadjuvant chemotherapy in breast cancer patients: correlation with pathological response grading system based on tumor cellularity | 강두경, 강석윤, 김구상, 김태희, 임현이, 정용식 |
| 2013 | | Oncologic outcomes after adjuvant chemotherapy using FOLFOX in MSI-H sporadic stage III colon cancer. | 김도윤, 김영배, 서광욱, 오승엽 |
| 2014 | | Phase II randomized trial of neoadjuvant metformin plus letrozole versus placebo plus letrozole for estrogen receptor positive postmenopausal breast cancer (METEOR). | 정용식 |
| 2014 | | Pretreatment selection of regimen according to genetic analysis improves the efficacy of chemotherapy in the first line treatment of metastatic colorectal cancer. | 김도윤, 김영배, 서광욱, 오승엽, 이제희 |
| 2015 | | Prevalence and characteristics of chemotherapy-related cognitive impairment in patients with breast cancer. | 박진희, 정용식 |
| 2017 | | Prognostic Significance of Lymphocyte Counts in Colon Cancer Patients Treated with FOLFOX Chemotherapy | 김영배, 노오규, 서광욱, 오승엽 |
| 2006 | | Sulforaphane sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-resistant hepatoma cells to TRAIL-induced apoptosis through reactive oxygen species-mediated up-regulation of DR5. | 김욱환, 최경숙 |
| 2016 | | The role of the addition of ovarian suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or regain menstruation after chemotherapy (ASTRRA): study protocol for a randomized controlled trial and progress | 정용식, 한세환 |
